I reported previously (see here) on new Israeli treatments for Acute Myeloid Leukemia (AML). Now the Hebrew University of Jerusalem and US biotech BioTheryX are developing a single molecule that attacks multiple leukemia proteins simultaneously. Lab tests show a 50% … Continue reading →

Israel’s BioSight is pleased with its Phase I/IIa study to evaluate the safety and efficacy of its Astarabine treatment for Acute Myeloid Leukemia (AML) and relapsed/refractory Acute Lymphoblastic Leukemia (ALL).  Full results later this year.  (See also 1st Nov newsletter). … Continue reading →

Latest reports of Phase II trials of BL-8040 from Israel’s Bioline Rx (see Nov newsletter), show that 38% of patients with acute myeloid leukemia, went into complete remission after just two cycles of the treatment.  All these patients had previously … Continue reading →

Israel’s BiolineRx has reported positive results from Phase II trials of its BL-8040 treatment in relapsed or refractory acute myeloid leukemia (r/r AML). It had a triple positive effect on the leukemic cells only two days after a single cycle … Continue reading →

The US FDA and the European Medicines Agency have awarded Israel’s stem cell therapy developer Gamida Cell orphan status for its NiCord leukemia treatment. NiCord treats acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin lymphoma and myelodysplastic syndrome. http://www.globes.co.il/en/article-gamida-cell-leukemia-treatment-granted-orphan-drug-status-1000998856

The United States FDA has granted orphan drug status to Israeli biotech BioLineRX’s BL-8040 treatment of acute myeloid leukemia. Because there are limited alternatives, BioLineRX will now receive US Federal support, financial assistance and market exclusivity. http://www.globes.co.il/serveen/globes/docview.asp?did=1000878182&fid=1725

Stanford Institute for Stem Cell Biology and Regenerative Medicine is to using the AML(acute myeloid leukemia) detection kits from Israel’s Sequentify (see here previously) in its leukemia research. Sequentify’s Infiniseq technology cuts DNA sequencing time to only 3.5 hours. https://www.prnewswire.com/il/news-releases/stanford-to-use-sequentify-kits-for-hematological-malignancies-ngs-sequencing-301981511.html

Professors from the Hebrew University of Jerusalem and the Hadassah Cancer Research Institute are leading CanceRNA – a European consortium working to develop novel immunotherapy treatments for cancer. The consortium will initially focus on treating acute myeloid leukemia. https://www.jns.org/israelis-lead-intl-hunt-for-innovative-cancer-treatments/

As soon as Phase 3 results were published, Israel added the new combo-therapy of venetoclax and azacytidine from global biotech AbbVie to the basket of treatments for acute myeloid leukemia (AML). Israel had the most patients enrolled in the Phase … Continue reading →